fulvestrant
Not Tagged
['breast']
sonia. compares the use of cdk4/6 inhibitors as first or second line treatment in advanced er+/her2-ve breast cancer. pfs not maintained when switching to second line on progression. os survival data overlapping. sonia challenges the need for 1l cdk4/6i. #asco23 
Early Career Consultant Clinical Oncologist (Breast and Thyroid Cancer). Interested in history, politics and sci-fi. Enthusiastic.Getting on with it. Views own.